A long patent battle against Momenta and Sandoz has ended in Amphastar’s favor, freeing the small drugmaker from the threat of almost $1B in damages.
U.S. Merck's shingles vaccine Zostavax faces a growing challenge in court.
Purdue, which has been fending off lawsuits over pain drug OxyContin in the U.S., may have to face off against Canada’s federal government.
Price-fixing allegations against generics makers just keep piling up, with Mylan, Teva and other players targeted in yet another lawsuit.
Takeda's blockbuster cancer med Velcade, previously set for copycat competition this year, won an appeals court ruling preserving sales for years.
In the fraud trial of Martin Shkreli, former Retrophin executives painted a picture of biotech entrepreneur who was both brilliant and irresponsible.
Beleaguered Insys faces yet another legal challenge with Anthem's decision to take the opioid drugmaker to court.
Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
Two former Insys saleswomen have copped to charges that they took part in a kickback scheme designed to push sales of pain drug Subsys.
Israel’s Teva is suing a former U.S. employee over allegations she shared company secrets with her boyfriend, the CEO of rival Apotex.